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The purpose of this study was to examine the distribution of two distinct follicle-stimulating hormone
receptor (FSHR) variants, Asn680Ser and Thr307Ala, in normaly ovulated   group of females from Ukraine.
The FSHR gene variants, Asn680Ser and Thr307Ala, were analyzed by PCR and RFLP. The strong linkage
disequilibrium  between FSHR307 and FSHR680 loci was found (p < 0.0001). The following genotypes have 
been detected: NN (33.1 %), NS (52.3 %), SS (14.6 %) for Asn680Ser variant and  TT (33.1 %), TA (55.4 %),
AA (11.5 %) for Thr307Ala variant. Further study on the association of FSHR variant with ovarian
dysfunction and individual susceptibility to FSH-stimulation considering our population data would clarify
a possible functional role of FSHR307 and FSHR680 loci.
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Introduction. Follicle stimulation hormone (FSH) is
one of the pituitary glycoproteins which are essential
for the normal gonadal function. It coordinates and
regulates gonadal growth, differentiation, endocrine
function and gametogenesis in both sexes [1, 2]. 
The effects of FSH are mediated through the
binding to a specific cell surface receptor, FSHR.
FSHR belongs to the large family of G-protein-coupled 
receptors, which span the plasma membrane seven
times and transduce the biological action of FSH, using 
cyclic AMP (cAMP) as the main intracellular
secondary messenger [3]. The FSHR gene contains a
single large exon, which encodes the transmembrane
and intracellular domains, and nine smaller exons
which encode the extracellular domain [4].
Theoretically mutations in the FSH receptor might
lead to an impaired signal transduction and thereby to a
diminished ovarian reserve. The first inactivating
mutation of the FSH receptor was described in 1995 in
some Finnish families with primary ovarian failure, the
so-called pure gonadal dysgenesis [5]. Since this
mutation was relatively frequent in the Finnish
population, it was originally thought that FSH receptor
mutations in general could constitute a common defect
in ovulation failure and amenorrhea. An `ad hoc’ assay
for the rapid detection of mutations was developed
based on the hybridization of a labelled probe, but the
successive application of such an assay to DNA
samples obtained from subjects of different ethnic
origin revealed a selective enrichment of the mutation
only in the Finnish population, while it turned out to be
extremely rare in other ethnic groups [6]. It was also
clear that mutations must occur in homozygous or
compound heterozygous states in order to produce a
reproductive phenotype [4]. A sporadic heterozygous
Val241Ala mutation found in one infertile male did not
impair the receptor function in vitro [7] and it was
318
ISSN 0233-7657. Á³îïîë³ìåðè ³ êë³òèíà. 2008. Ò. 24. ¹ 4
 G. B. LIVSHYTS, S. S. PODLESNAJA, S. A. KRAVCHENKO,
     L. A. LIVSHITS, 2008
judged not to be responsible for the phenotype. After
the description of a few other mutations occurring
spontaneously in sporadic cases of primary or early
secondary amenorrhea [8], the FSH receptor mutations
are commonly considered as a very rare cause of
infertility.
Only one naturally occurring activating mutation of 
the FSH receptor has been reported in a
hypophysectomized male who had normal
spermatogenesis under testosterone substitution  in
spite of undetectable serum gonadotrophin levels [9].
No activating mutations of FSH receptor in the
presence of normal pituitary function have been
reported, suggesting that such mutations might not
result in any phenotype if the pituitary gonadal axis is
otherwise  normal [10].
The experience of the last decade has clearly shown 
that mutations of the FSH receptor are very rare. This
finding is consistent with the indispensable role of FSH 
in human reproduction, so that mutations abolishing
gonadotrophin activity are self-eliminating. However,
the screening of several hundreds of patients and
controls world-wide  led to the discovery of single
nucleotide polymorphisms (SNPs) in the FSH receptor
gene and to the subsequent study of the correlation
between polymorphisms and gonadal function.
Today two SNPs, originally described by
Aittomaki et al., are well known [5]. These two
non-synonymous SNPs with frequencies of > 30 % in
the normal population have been identified in the
coding region of exon 10 of the FSH receptor gene. The 
first is located at position 919 (numbering according to
the translational start codon with ATG  as 1 in which A
is substituted by G, changing codon 307 from threonine 
(ACT) to alanine (GCT)). 
The second one is located at nucleotide position
2039 in which G is replaced by A. This leads to an
amino acid change at position 680 from serine (AGT)
to asparagine (AAT) [5].
The purpose of this study is to examine the
distribution of two distinct FSHR gene variants,
Asn680Ser and Thr307Ala, in normaly ovulated
females from Ukraine.
Materials and Methods. Subjects. SNPs analysis
of the FSH receptor gene was performed in 130
individuals from Ukraine after informed consent. 
DNA isolation. DNA was extracted from the
peripheral blood leukocytes by standard
phenol-chloroform extraction method [11].
PCR analysis. To analyze the FSHR transition G to
A in position 2039 (Asn680Ser variant), polymerase
chain reaction (PCR) amplification of the fragment of
exon 10 was performed using specific oligonucleotide
primers, as described elsewhere [12]. For the FSHR
transition A to G  in position 919 (Thr307Ala variant),
PCR amplification of the exon 10 fragment was
performed in one step with specific oligonucleotide
primers, which were used in the second step of nested
PCR, described by Sudo et al. [13]. 
The PCR reaction was performed in a final volume
of 25 µl containing 1 × PCR buffer, 1,5 mM MgCl2, 200 
µM of each dNTP, 1 µM of each primer, 0,2 units of
Taq-DNA polymerase («BioLabTech», USA) and
200 ng of the DNA template. The cycling conditions
for Asn680Ser variant were as follows: initial
denaturation at 94 oC for 5 min, 30 cycles consisting of
denaturation at 94 °C for 40 s, annealing at 55 oC for
40 s, extension at 72 oC for 40 s and a final elongation
step at 72 oC for 3 min.
The cycling conditions for Thr307Ala variant were
as follows: initial denaturation at 94 oC for 5 min, 2
cycles consisting of denaturation at 94 oC for 45 s,
annealing at 56 oC for 50 s, extension at 72 oC for 50 s, 5 
cycles consisting of denaturation at 94 oC for 45 s,
annealing at 53 oC for 50 s, extension at 72 oC for 50 s,
23 cycles consisting of denaturation at 94 oC for 45 s,
annealing at 51 oC for 45 s, extension  at  72 oC for 50 s
and a final elongation step at 72 oC for 7 min.
The PCR products were 520 and 364 bp long
correspondently.
RFLP analysis of the Asn680Ser and Thr307Ala
variants. The G to A transition in Asn680Ser variant
creates a restriction site for endonuclease BseN1I. For
the Thr307Ala variant a mismatch nucleotide has been
introduced in one of the primers (13). This mismatch
and the A to G transition creates an Eco81I restriction
site. 
The PCR products of exon 10 were digested with
BseN1I for Asn680Ser variant and Eco81I for
Thr307Ala variant. Digestion was performed in 15 µl
reaction volume containing 1 X reaction buffer, 0,5
units of the restriction enzyme and 10 µl of purified
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PCR product, incubated at 60 oC for 2 hours for
Asn680Ser variant and 37 oC  overnight for Thr307Ala
variant. Restriction endonuclease digestion products
with marker were visualized in  2.0 % agarose gel and
photographed. 
 Statistical analysis was performed by χ2 test,
Fisher’s exact test, likelihood-ratio test and
Expectation-Maximization (EM) algorithm using
GENEPOP [14] and ARLEQUIN [15] packages;
p < 0.05 was considered as significant. 
Results and Discussion. Based on the RFLP
analysis of Asn680Ser variant, patients were classified
into three groups: NN (680Asn/Asn), NS (680Asn/Ser) 
and SS (680Ser/Ser). Three different patterns could be
observed for Asn680Ser variant: a 520 bp band (for
680 Asn/Asn), a 520 bp and a 413 bp bands (for 680
Asn/Ser), and a 413 bp band (for 680 Ser/Ser) (Fig. 1).
The following genotypes distribution has been
detected: NN (33.1 %), NS (52.3 %), SS (14.6 %).
The presence of three different patterns was also
observed for Thr307Ala variant: a 364 bp band (for 307 
Thr/Thr), a 364 bp and a 328 bp bands (for 307
Thr/Ala) and a 328 bp band (for 307 Ala/Ala) (Fig. 2).
The small 36 bp band has run out from the gel. Based
on this RFLP analysis of Thr307Ala variant, patients
were classified into three groups namely, TT
(307Thr/Thr), TA (307Thr/Ala) and AA (307Ala/Ala). 
The following distribution of genotypes has been
detected: TT (33.1 %), TA (55.4 %), AA (11.5 %).
The observed genotype distributions showed no
deviations from Hardy-Weinberg expectations.    The
strong linkage disequilibrium between FSHR307 and
FSHR680 loci studied by likelihood-ratio test was
revealed in the investigated group (p < 0.0001).
Concerning two Asn680Ser and Thr307Ala
polymorphic variants in exon 10 we may unite them in
four possible allelic combinations, i. e. Thr307-Asn680 
(allele TN), Ala307-Ser680 (allele AS),
Ala307-Asn680 (allele AN) and Thr307-Ser680 (allele 
TS). We calculated maximum likelihood allele
frequencies using EM algorithm for two loci (data
shown in Table).
The distribution of several allelic variants of the
FSHR gene has been described in different populations
[12, 13, 16]. The analyses of FSHR variants
Thr307-Asn680 (TN) and Ala307-Ser680 (AS) have
demonstrated that alleles TN and AS are very common
(55.1 % and 35.1 %),while the alleles AN and TS are
found in Ukrainian population only in 5.7 % and 4.1 %
correspondently.
 Several studies were aimed to find correlation
between the frequency distribution of   FSH receptor
polymorphisms and ovarian function [17–20]. The
studies based on large number of patients identified a
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Fig. 1. RFLP analysis of Asn680Ser FSH receptor gene variant (2 %
agarose gel electrophoresis): 1 – homozygote variant Ser680Ser; 2,
3, 4 – heterozygote variant Asn680Ser; 5 – homozygote variant
Asn680Asn; 6 – molecular mass marker (Ladder 100 bp)
Fig. 2. RFLP analysis of Thr307Ala FSH receptor gene variant (2 %
agarose gel electrophoresis): 1, 2, 3 – homozygote variant
Thr307Thr; 4, 6, 8 – heterozygote variant Thr307Ala; 7 – homozy-
gote variant Ala307Ala; 5 – molecular mass marker (Ladder 100 bp)
significant correlation between the heterozygous
TN/AS genotype and polycystic ovaries (PCO) (see
[18]) and between the homozygous Ser at position 680
and type II amenorrhea (according to WHO
classification). Moreover, the identification of FSHR
allelic variants inspired the investigation of their
potential role as predictors of the ovarian response to an 
exogenous stimulation protocol [12]. However, in the
work of Laven et al. the ovarian response after the
induction of ovulation was shown to be similar for all
genotypes [21]. Such contradiction may be connected
to a possibly different biological meaning of
Asn680Ser and Thr307Ala polymorphisms. In this
study we analyzed the genotype distribution in
normaly ovulated   group. The observed genotype
distribution in the analyzed group from Ukraine
showed no deviations from Hardy-Weinberg
expectations. It seems to evidence that there is no
selection against any genotype in the analyzed group of 
normaly ovulated   females.  The population data,
obtained here, will be used as controls for further study
on the association of the FSHR variants with ovarian
dysfunction and individual susceptibility to
FSH-stimulation to clarify a possible functional role of
Asn680Ser and Thr307Ala polymorphisms.
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Ã. Á. Ë³âøèöü, Ñ. Ñ. Ïîäëºñíà, Ñ. À. Êðàâ ÷åí êî, Ë. À. Ë³âøèöü 
Ðîç ïîä³ë ïîë³ìîð ôíèõ âàð³àíò³â ëî êóñ³â FSHR307 òà FSHR680
10-ãî åê çî íà ãåíà FSHR ó ãðóï³ æ³íîê ç Óêðà¿ íè
Ðå çþ ìå
Ïðî à íàë³çî âà íî ðîç ïîä³ë ïîë³ìîð ôíèõ âàð³àíò³â Asn680Ser ³
Thr307Ala ãåíà ðå öåï òî ðà ôîë³êó ëîñ òè ìó ëþ âàëü íî ãî ãîð ìî íó
(FSHR) ó æ³íîê ç íîð ìàëü íîþ îâó ëÿö³ºþ ç Óêðà¿ íè. Ïîë³ìîðôí³
âàð³àíòè ãåíà FSHR äîñë³äæó âà ëè ìå òîäàìè ÏËÐ- òà
ÏÄÐÔ-àíàë³çó. Âè ÿâ ëå íî íåð³âíî âà ãó çà  ç÷åï ëåí íÿì ì³æ ëî êó -
ñà ìè FSHR307 òà FSHR680 (p < 0,0001). ²äåí òèô³êî âà íî  ãå íî -
òè ïè NN (33,1 %), NS (52,3 %), SS (14,6 %) äëÿ âàð³àíòà
Asn680Ser òà TT (33,1 %), TA (55,4 %), AA (11,5%) – äëÿ
âàð³àíòà Thr307Ala. Çâà æà þ ÷è íà îò ðè ìàí³ ïî ïó ëÿö³éí³ äàí³,
ïîä àëü øå âèâ ÷åí íÿ àñîö³àö³¿ ïîë³ìîð ôíèõ âàð³àíò³â ãåíà FSHR
ç äèñ ôóíêö³ºþ ÿº÷íèê³â òà ³íäèâ³äó àëü íîþ ÷óò ëèâ³ñòþ äî
FSH-ñòè ìó ëÿö³¿, ìîæ ëè âî, äîïîìîæå âèç íà ÷èòè ôóíêö³îíàëü -
íó ðîëü ëî êóñ³â FSHR307 òà FSHR680. 
Êëþ÷oâ³ ñëî âà: ãåí FSHR, ïîë³ìîðô³çì, ïî ïó ëÿö³ÿ.
À. Á. Ëèâ øèö, Ñ. Ñ. Ïîä ëåñ íàÿ, Ñ. À. Êðàâ ÷åí êî, Ë. À. Ëèâ øèö 
Ðàñ ïðå äå ëå íèå ïî ëè ìîð ôíûõ âà ðè àí òîâ ëî êó ñîâ FSHR307 
è FSHR680 10-ãî ýê çî íà ãåíà FSHR â ãðóï ïå æåí ùèí 
èç Óêðà è íû
Ðå çþ ìå
Ïðî à íà ëè çè ðî âà íî ðàñ ïðå äå ëå íèå ïî ëè ìîð ôíûõ âà ðè àí òîâ
Asn680Ser è Thr307Ala ãåíà ðå öåï òî ðà ôî ëè êóë ëîñ òè ìó ëè ðó þ -
ùå ãî ãîð ìî íà (FSHR) â ãðóï ïå  æåí ùèí ñ íîð ìàëü íîé îâó ëÿ öè åé 
èç ïî ïó ëÿ öèè Óêðà è íû. Ïî ëè ìîð ôíûå âà ðè àí òû Asn680Ser è
Thr307Ala ãåíà FSHR èñ ñëå äî âà ëè ìå òî äà ìè ÏÖÐ- è
ÏÄÐÔ-àíà ëè çà. Âû ÿâ ëå íî íå ðàâ íî âå ñèå ïî ñöåï ëå íèþ ìåæ äó
ëî êó ñà ìè FSHR307 è FSHR680 (ð < 0,0001). Èäåí òè ôè öè ðî âà -
íû ãå íî òè ïû NN (33,1 %), NS (52,3 %), SS (14,6 %) äëÿ âà ðè àí òà 
Asn680Ser  è TT (33,1%), TA (55,4 %), AA (11,5 %) – äëÿ âà ðè àí òà 
Thr307Ala. Îñíî âû âà ÿñü íà ïî ïó ëÿ öè îí íûõ äàí íûõ, äàëü íåé -
øåå èç ó÷å íèå àñ ñî öè à öèè ïî ëè ìîð ôíûõ âà ðè àí òîâ ãåíà FSHR ñ
äèñ ôóí êöè ÿ ìè ÿè÷ íè êîâ è èí äè âè äó àëü íîé ÷ó âñòâè òåëü íîñ òüþ 
ê FSH-ñòè ìó ëÿ öèè, âîç ìîæ íî, ïðî ÿñ íèò ôóíê öè î íàëü íóþ ðîëü 
ëî êó ñîâ FSHR307 è FSHR680.
Êëþ ÷å âûå ñëî âà:  ãåí FSHR, ïî ëè ìîð ôèçì, ïî ïó ëÿ öèÿ.
REFERENCES
1. Gharib S. D., Wierman M. E., Shupnik M. A., Chin W. W.
Molecular biology of pituitary gonadotropins // Endocrinol.
Rev.–1990.–11.–P. 177–199.
2. Moyle W. R., Campbell R. K. Gonadotropins //  Reproductive
endocrinology, surgery and technology / Eds E. Y. Adashi, J.
A. Rock, Z. Rosenwalks.–Lippincott-Raven, 1996.–
P. 683–724.
3. Segaloff D. L., Ascoli M. The lutropin/choriogonadotropin
receptor: 4 years later // Endocrinol. Rev.–1993.–14.–P. 324– 
342.
4. Simoni M., Gromoll J., Nieschlag E. The follicle-stimulating
hormone receptor: biochemistry, molecular biology and
pathophysiology // Endocrinol. Rev.–1997.–18.–P. 739–773.
5. Aittomaki K., Lucena J. L., Pakarinen P., Sistonen P.,
Tapanainen J., Gromoll J., Kaskikari R., Sankila E. M.,
Lehvaslaiho H., Engel A. R., Nieschlag E., Huhtaniemi I., de
321
DISTRIBUTION OF FSHR307 AND  FSHR680  ALLELIC VARIANTS OF FSH RECEPTOR GENE EXON 10
 Population Subjects (n) TN, % AN, % TS, % AS, %
Ukrainian 130 55,1 5,7 4,1 35,1
United Kindom 51 60 0 0 40
Chinese 236 61 5 5 29
Distribution of FSH receptor gene alleles TN, AN, TS, and AS among populations [19, 20]
la Chapelle A. Mutation in the follicle-stimulating hormone
receptor gene causes hereditary hypergonadotropic ovarian
failure // Cell.–1995.–82, N 6.–P. 959–968. 
6. Jiang M., Aittomaiki K., Nilsson C., Pakarinen P., Iitia A.,
Torresani T., Simonsen H., Goh V., Pettersson K., de la
Chapelle A. The frequency of an inactivating point mutation
(566C → T) of the human follicle-stimulating hormone
receptor gene in four  populations using allele-specific
hybridization and time-resolved fluorometry // J. Clin.
Endocrinol. Metab.–1998.–83.–P. 4338–4343.
7. Simoni M., Gromoll J., Hoppner W., Kamischke A., Krafft T.,
Stahle D., Nieschlag E. Mutational analysis of the
follicle-stimulating hormone (FSH) receptor in normal and
infertile men: identification and characterization of two
discrete FSH receptor  isoforms // J. Clin. Endocrinol.
Metab.–1999.–84.–P. 751–755.
8. Beau I., Touraine P., Meduri G., Gougeon A., Desroches A.,
Matuchansky C., Milgrom E., Kuttenn F., Misrahi M. A novel 
phenotype related to partial loss of function mutations of the
follicle stimulating hormone receptor // J. Clin.
Invest.–1998.–102.–P. 1352–1359.
9. Gromoll J., Simoni M., Nieschlag E. An activating mutation
of the follicle-stimulating hormone receptor autonomously
sustains spermatogenesis in a hypophysectomized man // J.
Clin. Endocrinol. Metab.–1996.–81.–P. 1367–1370.
10. Simoni J. M. Keeping it up: maintaining adherence to
antiviral therapies // Body Posit.–1998.–11, N 4–5.–P. 20–
23.
11. Maniatis T., Fritsch E. F., Sambrook J. Molecular cloning: a
laboratory manual.–New York: Cold Spring Harbor Lab.
press, 1982.–545 p. 
12. Laven J. S., Mulders A. G., Suryandari D. A., Gromoll J.,
Nieschlag E., Fauser B. C., Simoni M. Follicle-stimulating
hormone receptor polymorphisms in females with
normogonadotropic anovulatory infertility // Fertility and
Sterility.–2003–80.–P. 986–999.
13. Sudo S., Kudo M., Wada S., Sato O., Hsueh A. J., Fujimoto S.
Genetic and functional analyses of polymorphisms in the
human FSH receptor gene // Mol. Hum. Reprod.–2002.–8,
N 10.–P. 893–899.
14. Raymond M., Rousset F. GENEPOP (version 1.2): population 
genetics software for exact tests and ecumenicism // J.
Heredity.–1995.–86.–P. 248–249.
15. Excoffier L., Laval G., Schneider S. Arlequin ver. 3.0: An
integrated software package for population genetics data
analysis // Evolution. Bioinform. Online.–2005.–1.–P. 47–
50.
16. Loutradis D., Patsoula E., Minas V., Koussidis G. A.,
Antsaklis A., Michalas S., Makrigiannakis A. FSH receptor
gene polymorphisms have a role for different ovarian
response to stimulation in patients entering IVF/ICSI-ET
programs // J. Assist. Reprod. Genet.–2006.–23, N 4.–P. 177– 
184.
17. Da Fonte K. M. B., Batista M. C., Russel A. J., Vass K.,
Giacaglia L. R., Mendonca B. B., Latronico A. C. No
evidence of the inactivating mutation (C566T) in the
follicle-stimulating hormone receptor gene in Brazilian
females with premature ovarian failure //  Fertility and
Sterility.–1998–70.–P. 565–567.
18. Liu J. Y., Gromoll J., Cedars M. I., La Barbera A. R.
Identification of allelic variants in the follicle-stimulating
hormone receptor genes of females with or without
hypergonadotropic amenorrhea //  Fertility and Sterility.–
1998–70.–P. 326–331.
19. Conway G. S., Conway E., Walker C., Hoppner W., Gromoll
J., Simoni M. Mutation screening and isoform prevalence of
the follicle stimulating hormone receptor gene in females
with premature ovarian failure, resistant ovary syndrome and
polycystic ovary syndrome // Clin.
Endocrinol.–1999.–51.–P. 97–99.
20. Tong Y., Liao W. X., Roy A. C., Ng S. C. Absence of mutations 
in the coding regions of the follicle-stimulating hormone
receptor gene in Singapore Chinese females with premature
ovarian failure and polycystic ovary syndrome // Hormî nå
Metab. Res.–2001.–33.–P. 21–26.
21. Perez  M. M., Gromoll J., Behre H. M., Gassner C., Nieschlag 
E., Simoni M. Ovarian response to Follicle-Stimulating
Hormone (FSH). Stimulation depends on the FSH receptor
genotype // J. Clin. Endocrinol. Metabol.–2000.–85.–P.
3365–3369.
ÓÄÊ 575.11 + 577.21
Íàä³éøëà äî ðå äàêö³¿ 04.02.08 
322
LIVSHYTS G. B. ET AL.
